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To establish whether efficient suppression of virus replication in HIV-2-infected individuals is associated with low replicative capacity of HIV-
2, replication kinetics of HIV-2 variants from long-term aviremic individuals was analyzed and compared with that of the relatively slow-
replicating HIV-1 variants from asymptomatics and long-term nonprogressors (AS/LTNP). On average, HIV-2 from aviremic individuals had
lower replication rates than HIV-1 variants from AS/LTNP in cells of 8 donors (0.45 log10 [range 0.14–0.77] vs. 0.58 log10 [range 0.32–0.99] pg
RT/ml/day, P = 0.036). The relatively low replication rate of HIV-2 compared to HIV-1 variants was not related to different sensitivities to
inhibition by CD8+ T cells or different degrees of infectivity. HIV-2 replication rates increased with progressive infection and with switch from
CCR5 to CXCR4 usage.
The relatively low replicative capacity of HIV-2 variants from aviremic individuals likely contributes to the low viral load and benign course of
infection in these individuals.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-2; Biological clone; Replication rate; Aviremia; Long-term nonprogressor; PathogenesisIntroduction
Although both HIV-1 and HIV-2 infection cause AIDS in
humans, HIV-2-infected individuals generally remain AIDS-
free for longer periods and have lower mortality rates than HIV-
1-infected individuals (Whittle et al., 1994; Marlink et al., 1994;
Marlink, 1996; Ricard et al., 1994; Poulsen et al., 1997; Berry
et al., 2002). In fact, the relatively high prevalence of HIV-2 in
older people and a mortality rate in these individuals that is
similar to that of uninfected individuals suggest that although⁎ Corresponding author. Department of Virology, Room Ee1742a, Erasmus
MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands. Fax: +31 10
4089485.
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doi:10.1016/j.virol.2006.05.029some HIV-2-infected individuals progress to AIDS at a similar
rate as HIV-1-infected individuals, many may never develop
AIDS during their lifetime (Poulsen et al., 1989, 1997, 2000;
Larsen et al., 1998; Ricard et al., 1994). During asymptomatic
HIV-2 infection, plasma loads are often too low to be detected
using sensitive RT-PCR techniques, which contrasts with
asymptomatic HIV-1 infection, where even long-term nonpro-
gressors (LTNP) often have low but detectable plasma loads
(Berry et al., 1998; Gottlieb et al., 2002; Popper et al., 1999;
Damond et al., 2002; Cao et al., 1995; Barker et al., 1998; Blaak
et al., 1998; Rodes et al., 2004). We have previously observed
that also the infectious PBMC load is very low in aviremic HIV-
2-infected individuals, in a range comparable to that in HIV-1-
infected individuals treated with HAART, and similar to only a
small minority of asymptomatically HIV-1-infected individuals
(Blaak et al., 2004).These findings suggest a qualitative
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and HIV-2 infection. Moreover, while a high level of control
and long-term nonprogression appears common in HIV-2
infection, it is exceptional in HIV-1 infection.
In HIV-1 infection, the level of virus control is in part
attributable to the efficiency of the triggered immune response
(Sewell et al., 2000; Xiao et al., 2002). Secondly, it is correlated
with the ex vivo replication capacity of HIV-1 variants (Connor
et al., 1993; Asjo et al., 1986; Connor and Ho, 1994; Blaak et
al., 1998; Campbell et al., 2003; Quinones-Mateu et al., 2000).
Although a high replicative capacity is often associated with the
‘SI’ or CXCR4-using phenotype, differences in in vitro
replicative capacity were also observed between CCR5-
restricted HIV-1 variants from LTNP and individuals who
develop AIDS, and between individuals with low or high viral
load (Blaak et al., 1998; Campbell et al., 2003; Quinones-Mateu
et al., 2000), demonstrating that replicative capacity can evolve
independently of coreceptor usage (Blaak et al., 1998; Connor
and Ho, 1994).
The main objective of this study was to establish whether
the relatively high level of virus control in HIV-2-infected
individuals is associated with a relatively low replicative
capacity of the infecting variants. For this purpose, we have
compared replication kinetics of HIV-2 variants isolated fromTable 1
Subject characteristics
Individual Nat a HIV subtype Time point
(months) b
CD4
(/μl) c
RNA
(/ml) c
HIV-2 AS/LTNP
RH2-3 CVI A 96 770 <500*
RH2-8 GH B 80 900 <500
RH2-13 CVI A 52 900 <500
RH2-14 CVI A 51 550 <500
RH2-22 CVI B 30 670 <500
HIV-1 AS/LTNP
RH1-1 NIG A 70 1150* <500*
RH1-2 GAM A/G 41 760* 24,600*
ACH78 NL B 17 750 <1000
ACH441 NL B 16 1110 <1000
ACH583 NL B 24 830 <1000
ACH750 NL B 16 1420 19,000
HIV-2 progressors
RH2-1 CVI A 57 240 NT
RH2-5 CVI A 38 120 110,000
RH2-7 CVI A 33 10 +
RH2-21 CVI A 1 60* 59,000
RH2-24 CVI A 4 70* 23,000
RH2-26 NL B 1 10 330,000
a Country of origin: CVI = Cape Verde Islands, GH = Ghana, NL = Netherlands,
b Time between first visit to the clinic and the sample of virus isolation.
c CD4 numbers and RNA copies at the time point of virus isolation, when unavail
PCR used for load determination at the moment of virus isolation was 500 copies ml−1
for the Amsterdam Cohort (ACH) participants. NT = not tested. + = positive, not q
d Infectious Units per Million CD4+ T cells.
e Length of known asymptomatic follow-up, NA = not applicable.
f LTNP = long-term nonprogressor, AS = asymptomatic individual, PROG = prog
g CCR5 and CXCR4 usage of infecting variants based on results with CCR5−\− PB
R5/X4 = individuals with co-existing CCR5-using and CXCR4-using variants.untreated, long-term aviremic individuals with that of the –
for HIV-1 standards – relatively slow HIV-1 variants from
LTNP (Blaak et al., 1998). Because previous studies had
demonstrated the existence of different HIV-2 replication
phenotypes in PBMC and cell lines and suggested an
association with stage of disease (Albert et al., 1990; Castro
et al., 1990), we also determined whether HIV-2 variants from
individuals who control infection have different replicative
capacity in PBMC than HIV-2 variants from individuals who
progress to AIDS.
Results
Subjects and time points of analysis
Of 11 asymptomatic HIV-1 and HIV-2-infected individuals
included, 10 had a known seropositive follow-up of 7.3 to
12.6 years with high and stable CD4 counts and were termed
long-term nonprogressors (LTNP) (Table 1). At the moment of
virus isolation, the CD4+ T cell numbers of HIV-1 AS/LTNP
were slightly higher than that of the HIV-2 LTNP (average 1003
vs. 758 cells per μl of blood respectively; P = 0.2, Mann-
Whitney U). Four of 6 HIV-1-infected AS/LTNP and all 5 HIV-
2-infected LTNP had undetectable plasma load. The HIV-2PBMC load
(IUPM d)
AS follow-up
(months/years) e
Disease stage f CCR5 and
CXCR4 usage g
0.2 151/12.6 LTNP R5
0.01 134/11.1 LTNP R5
0.6 112/9.3 LTNP R5
0.3 100/8.3 LTNP R5
0.9 87/7.3 LTNP R5
10 112/9.3 LTNP R5
3 78/6.5 AS R5
2 124/10.3 LTNP R5
1 149/12.4 LTNP R5
1 138/11.5 LTNP R5
16 148/12.3 LTNP R5
36 NA PROG R5
10 NA PROG R5
673 NA PROG R5
1 NA PROG R5/X4
63 NA PROG R5/X4
71 NA PROG R5/X4
NIG = Nigeria, GAM = Gambia.
able data from the next time point were taken (*). The detection limit of the RT-
for the HIV-2-infected individuals and RH1-1 and RH1-2, and 1000 copies ml−1
uantified.
ressor.
MC and GHOST or U87 cells. R5 = individuals with CCR5-using variants only,
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Mann-Whitney U). The lower viral load of the HIV-2-infected
LTNP, even though the moment of analysis was on average from
temporally more advanced stages (62 vs. 31months), reflects the
better control of virus replication in asymptomatic HIV-2 vs.
HIV-1 infection (Popper et al., 1999; Berry et al., 1998; Gottlieb
et al., 2002). HIV-2 progressors all had high virus loads and/or
low CD4 counts, and from 3 out of 6 CXCR4-using variants
were isolated (Table 1).
Replication kinetics of HIV-2 variants from aviremic LTNP vs.
HIV-2 variants from progressors
Replication kinetics of HIV-2 variants from aviremic LTNP –
all CCR5-restricted in PBMC (‘R5’ variants) – were compared
with R5 as well as CXCR4-restricted (X4) variants from
progressors. As a measure for replication, we determined the
accumulation of functional RTenzyme concentrations in culture
supernatants, reflecting newly synthesized virus particles
(Fig. 1a). Most variants had an S-shaped growth curve, with a
period of optimal growth preceded by a ‘lag-phase’ and followed
by a plateau-phase (Fig. 1a). The ‘lag-phase’ reflects the time
needed to reach the cut-off value of the assay. Because any
increase in supernatant RT during this phase is relative to the cut-
off value, slopes underestimate true replication rates. The most
rapid-replicating variants, particularly X4 variants, did not have
a ‘lag-phase’. The plateau-phase is characterized by gradually
declining slopes, presumably due to exhaustion and/or reduced
infectability of target cells (Campbell et al., 2003). For all three
groups of viruses, optimal growth was observed between days 3
and 5 (Fig. 1b). At this point, i.e., before growth started to
decelerate to various degrees for the different types of viruses,
the average level of RT accumulated was 0.74 log10 higher for
the R5 progressor than LTNP variants (1446 vs. 263 pg RT/ml;
P = 0.04, T test), indicating a higher replication rate. X4 variantsFig. 1. Replication kinetics of HIV-2 variants from LTNP vs. HIV-2 from progressors.
infected PBMC consisting of a mix of cells from 5 donors during 14 days of cultur
variants from progressors (middle) and X4 variants from progressors (right). Viruses
viruses are of subtype A. Dashed lines represent the cut-off value of the RT assay.
standard error of the mean. Arrow designates latest time point of optimal growth, as
from LTNP and progressors (Student's T test).had accumulated even higher levels, on average 1.4 log10
higher than LTNP variants (6794 pg RT/ml; P = 0.005, Mann-
Whitney U).
In contrast to X4 variants that all replicated rapidly, the R5
progressor variants were heterogeneous with respect to
replication phenotypes, ranging from variants with kinetics
similar to that of the LTNP variants to those nearly as rapid as
that of X4 variants (Fig. 1a). In none of the groups specific
differences between subtype A and B viruses were observed.
Replication kinetics of HIV-2 variants from LTNP vs. HIV-1
variants from AS/LTNP
To determine how replication kinetics of HIV-2 variants
from aviremic LTNP compares to that of the relatively slow-
replicating HIV-1 variants from AS/LTNP, we analyzed three
early stage subtype B HIV-1 variants from LTNP with typically
slow/intermediate phenotypes as revealed in our previous study
(Blaak et al., 1998). Subtype A and A/G HIV-1 variants from
AS/LTNP of West-African origin were additionally included, to
control for differences related to replication in hosts of different
ethnic origin.
Replication kinetics of subtype B and subtype A and A/GAS/
LTNP variants were similar in PBMC of 3 donors tested
(Fig. 2a). The relatively slow replication kinetics of these
variants for HIV-1 standards was confirmed by using as a
reference strain a R5 progressor variant with a previously
identified rapid replicating phenotype characteristic for late
stage HIV-1 (Blaak et al., 1998). On average, HIV-2 variants
from aviremic individuals had even lower replication kinetics
than the AS/LTNP HIV-1 variants (Fig. 2b). At the last time
point where growth rates were still optimal for both types of HIV,
HIV-1 RT concentrations were 0.76 log10 (donor A, day 5), 0.58
log10 (donor B, day 7) and 0.99 log10 (donor C, day 11) higher
than those of HIV-2.Accumulation of functional RT concentrations in culture supernatants of acutely
e. (a) Shown are individual growth curves of R5 variants from LTNP (left), R5
of LTNP RH2-8 and RH2-22, and progressor RH2-26 are of subtype B, all other
(b) Average growth curves for the three types of variants. Error bars represent
terisk indicates statistical significance at the P < 0.05 level between R5 variants
Fig. 2. Replication kinetics of HIV-2 variants from LTNP vs. HIV-1 from AS/LTNP. (a) Average RT accumulation in supernatants for 3 HIV-1 subtype B variants
(triangles) and 6 subtype A and A/G variants (circles) from AS/LTNP in PBMC of three different donors. A typically rapid progressor subtype B variant (squares) is
shown as reference. (b) Average RT accumulation in supernatants for 9 HIV-1 variants from AS/LTNP (the same as in panel a; black symbols) and 12 HIV-2 variants
from LTNP (white symbols). Arrows designate time points where growth becomes sub-optimal. In both panels a and b, error bars represent standard error of the mean
and asterisks indicate statistical significance at the P < 0.01 level (Student's T test).
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For each HIV variant and donor combination from the
experiment shown in Fig. 2, replication rates were calculated
based on the optimal increases in RT, assuming these represent
‘true’ growth rates, i.e., when target cell availability nor
infectability are rate limiting (Figs. 3a, b). HIV-2 and HIV-1
AS/LTNP growth rates were on average 0.44 log10 vs. 0.58 log10
pg RT/ml per day, 0.33 log10 vs. 0.44 log10 pg RT/ml per day and
0.14 log10 vs. 0.32 log10 pg RT/ml per day, for donors A, B and C
respectively (Fig. 3b). When continuously produced at these
rates for 13 days HIV-1 AS/LTNP variants will accumulate
1.4 log10 (donor B) to 2.6 log10 (donors A and C) higher amounts
of virus than the HIV-2 variants (Fig. 3c). For comparison, the
replication rate of the HIV-1 rapid progressor variant was
1.07 log10, 0.88 log10 and 0.82 log10 pg RT/ml per day in donors
A, B and C, respectively, extrapolating to 5.2–5.9 log10 higher
RT concentrations than the HIV-1 AS/LTNP variants after
13 days (Fig. 3c).
Based on the RT accumulation profiles from the experiment
shown in Fig. 1, HIV-2 LTNP viruses had an average growth
rate of 0.46 log10 pg/ml RT per day (range 0.39–0.56),
compared to 0.57 log10 (range 0.38–0.72; P = 0.03, T test) and
0.77 log10 (range 0.73–0.84) for R5 and X4 HIV-2 progressorvariants respectively (Fig. 3d). Of note, this average HIV-2
LTNP growth rate was very similar to that observed in cells of
donor A (0.44 and 0.46 log10; compare Figs. 3c and d),
suggesting similar replication rates for HIV-1 AS/LTNP (Fig.
3c) and HIV-2 R5 progressor (Fig. 3d) variants as well (0.58
log10 and 0.57 log10, respectively). In support of this, HIV-1
AS/LTNP and R5 HIV-2 progressor viruses had similar levels of
RT levels accumulated 7 days p.i. when directly compared in an
independent experiment (not shown).
Lower replication rate of HIV-2 vs. HIV-1 AS/LTNP is not
determined by CD8+ T cells
CD8+ T cells produce numerous factors that influence HIV-1
replication (reviewed by Tomaras and Greenberg (2001)). To
rule out the possibility that the observed differences between
HIV-1 and HIV-2 replication rates were explained by different
sensitivities to CD8+ T cell factors, we compared HIV-1 and
HIV-2 replication rates in PBMC from which CD8+ Tcells were
removed (Fig. 4a). The differences between HIV-1 and HIV-2
were in the same range as observed earlier, although P values
were higher (0.06–0.14) likely due to smaller group sizes.
Differ- ences were statistically significant when results in three
donors were combined (0.57 vs. 0.79 log10 pg/ml/day,
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in the absence of CD8+ T cells demonstrate that the slower
replication of HIV-2 variants is not explained by a higher
sensitivity to antiviral activity of CD8+ T cells. In fact,depletion of CD8+ T cells had a slightly larger effect on HIV-1
than on HIV-2 replication (Fig. 4b).
In whole PBMC as well as CD8-depleted PBMC of most
donors, the HIV-1 AS/LTNP variants displayed a broader range
Fig. 4. HIV-1 and HIV-2 replication rates in CD8+ T cell-depleted PBMC. (a) Comparison of growth rates from 7 HIV-2 LTNP variants and 5 HIV-1 AS/LTNP variants
in CD8+ T cell-depleted PBMC of cells of three donors. (b) The effect of CD8-depletion on HIV-1 and HIV-2 growth rates. Symbols represent the growth rate in CD8-
depleted PBMC minus that in whole PBMC of the same donor, determined for 12 HIV-2 LTNP variants and 9 HIV-1 AS/LTNP variants in cells of 2 different donors.
Dashed line indicates identical growth rates in CD8-depleted and whole PBMC. Both in panels a and b horizontal bars indicate average values and P values were
calculated using Mann-Whitney U test.
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Importantly, however, the majority of HIV-2 variants had growth
rates as low as, and often even lower than, the slowest of HIV-1
AS/LTNP variants.
Difference in HIV-2 LTNP and HIV-1 AS/LTNP replication
rates is not determined by differences in infectivity
In infection experiments, HIV-1 and HIV-2 inocula had been
equalized for functional RT content in virus stocks, which
reflects infectious particle content but still allows for differences
in infectivity per ‘RT unit’ or infectious particle. To determine
whether the lower replication kinetics of HIV-2 variants was
explained by lower infectivity at equal amounts of functional
RT, we estimated the frequency of cells infected with
replication-competent virus (i.e., infectious units) after exposureFig. 3. Replication rates and theoretical growth. (a) Calculation of replication rates usi
are RT accumulation and regression curves for three variants randomly selected from
curves are replication rates (b) Comparison of HIV-1 and HIV-2 replication rates base
a. Horizontal bars represent average values. P values were calculated using Student
accumulation of RTconcentrations assuming optimal growth throughout the culture p
averages for HIV-2 LTNP variants (open circle) and HIV-1 AS/LTNP variants (close
panel d, averages are shown for HIV-2 LTNP variants (circle), R5 progressor varian
standard error of the means.and determined replication kinetics in parallel cultures of the
same cells. Despite the lower replication rates of the HIV-2
compared to HIV-1 variants (Fig. 4a), average frequencies of
infectious units after 1 round of infection were similar (Fig. 5a),
demonstrating similar degrees of infectivity and suggesting
different levels of virus produced per productively infected for
HIV-1 and HIV-2.
Single cycle infectivity of the HIV-1 and HIV-2 variants
was additionally determined using GHOST-CCR5 cells. After
one round of replication, the percentages of GFP-expressing,
or actively virus-replicating cells, were comparable for HIV-1
and HIV-2 variants (Fig. 5b), confirming the results observed
in PBMC. The kinetics of GFP expression were slightly lower
in HIV-2-infected cells however, as evidenced by a delay in
the detection of GFP+ cells in the HIV-2-exposed cells (0.3%
vs. 0.7% positive cells 14 h p.i.) and a slower increase in meanng linear regression and based on the optimal increase in supernatant RT. Shown
the experiment shown in Fig. 2 in cells of donor A. Slopes (m) of regression
d on results from the experiment shown in Fig. 2 and obtained as shown in panel
's T test. (c, d) The obtained growth rates were used to calculate the theoretical
eriod for the experiments shown in Fig. 2 (panel c) and Fig. 1 (panel d). In panel c
d circle) are shown, as well as the rapid reference HIV-1 strain (dotted line), in
ts (triangle) and X4 progressor variants (inverted triangle). Error bars indicate
Fig. 5. Infectivity of HIV-2 variants from LTNP vs. HIV-1 from AS/LTNP. (a) The frequency of CD8+ T cell-depleted PBMC infected with replication competent virus
after acute infection. Results are based on samples of the inoculated cells used in the experiment shown in Fig. 4a. (b) Percentages of GFP-expressing GHOST-CCR5
cells analyzed 26 h after infection. In panels a and b, horizontal bars represent average values, P values are determined using the Mann-Whitney U test. (c) Kinetics of
GFP expression between 14 and 30 h after inoculation. Shown are the percentages of GFP+ cells (left) and mean fluorescence intensity in the GFP+ cells (right). Bars
represent standard errors of the means. Asterisks indicate P values significant at the 0.05 (*) or 0.01 (**) level calculated with Mann Whitney U test.
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17 h of infection (Fig. 5c). Since it is highly unlikely that re-
infection can be detected during the first 26 h p.i., the
observed increases in MFI and numbers of GFP-positive cells
probably reflect an increase in the levels of GFP expressed per
infected cell and the number of cells starting to produce GFP
above detection limits respectively, thus indicating a difference
in the kinetics of protein synthesis between HIV-1- and HIV-2-
infected cells.
Discussion
The present study is the first to characterize replication
properties of HIV-2 variants isolated from healthy infected
individuals who maintain low, undetectable plasma load for
prolonged periods. The study is also the first to compare the
replication kinetics of individual biological HIV-2 clones – as
opposed to bulk isolates – from different stages of infection as
well as biological HIV-1 clones.
We have shown that long-term healthy aviremic individuals
carry HIV-2 variants that have lower replication rates than
variants from individuals who progress to AIDS, demonstrat-
ing an association between in vitro replication capacity and
disease progression reminiscent of what is known for HIV-1
(Connor et al., 1993; Asjo et al., 1986; Connor and Ho, 1994;
Blaak et al., 1998; Campbell et al., 2003; Quinones-Mateu etal., 2000). Especially CXCR4 usage was strongly associated
with high replication rates, while CCR5-using variants were
more heterogeneous with respect to replicative capacity. Of
note, 2 of the progressor variants with relatively slow
replicative capacity were isolated from an individual who
was treated with AZT and 3TC at the moment of virus
isolation (RH2-5). Both variants contained a Q151M and
M184V mutation in RT (not shown) which are associated with
AZT and 3TC resistance respectively (Colson et al., 2005;
Descamps et al., 2004; Brandin et al., 2003; van der Ende et
al., 2000), and it cannot be excluded that in this case the low
replication capacity is related to reduced fitness associated
with these mutations.
HIV-2 variants from LTNPwere compared with the relatively
slow-replicating HIV-1 variants from AS/LTNP in cells of
8 different donors, resulting in average rates of 0.45 log10 (range
0.14–0.77) and 0.58 log10 pg RT/ml/day (range 0.32–0.99)
respectively. In comparison, the average replication rate in cells
of the same donors of the rapid HIV-1 reference strain was 0.98
log10 (range 0.71–1.32), indicating that the difference between
HIV-1 and HIV-2 from AS/LTNP is more subtle than that
between HIV-1 from LTNP and progressors. The magnitude of
the difference between HIV-2 and HIV-1 from AS/LTNP varied
between donors, and as an exception to a rule, HIV-1 AS/LTNP
replicated less efficiently than HIV-2 LTNP variants in cells of
one donor (not shown). This suggests the existence of specific
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that of HIV-1 AS/LTNP variants that are more replication
competent under most conditions. The nature of responsible host
factor(s) is not known but may be linked to our observation that
replication of HIV-1 variants was more affected by depletion of
CD8+ T cells than that of HIV-2 variants, suggestive of a higher
sensitivity to (one or more of) the virus inhibitory factors that are
produced byCD8+ Tcells (reviewed by Tomaras andGreenberg,
2001).
The low replicative capacity of HIV-2 variants from long-
term aviremic individuals compared to HIV-1 variants from AS
and LTNP has two implications. Firstly, since HIV-1 from LTNP
have relatively low replicative capacity for HIV-1 standards
(Blaak et al., 1998; Quinones-Mateu et al., 2000), the finding
illustrates the low replicative capacity of these HIV-2 variants
relative to HIV-1 in general. Principally, most of the HIV-2
variants had replication rates comparable to, or even lower than,
the slowest viruses among the HIV-1 variants presently studied.
One of these slow-replicating HIV-1 variants, isolated from
subject ACH78, was also among the slowest in our previous
study, which included 105 different HIV-1 variants from LTNP
and progressors (Blaak et al., 1998), suggesting this variant may
represent the slow extremity of naturally occurring HIV-1
replication phenotypes. Secondly, our findings suggest that
subtle differences in replicative capacity between HIV-1 and
HIV-2 variants may contribute to the different degrees of control
of virus replication generally observed between HIV-2 LTNP
and HIV-1 LTNP (Cao et al., 1995; Barker et al., 1998; Blaak
et al., 1998; Rodes et al., 2004).
We did not observe differences in infectivity between HIV-1
and HIV-2, suggesting both types of HIV have similar entry
efficiencies, although we cannot rule out that polybrene present
in culture medium differentially affects the entry of different
viruses. Nevertheless, our results exclude differences in
infectivity as basis for the here observed lower virus production
rate of HIV-2 and suggest that cells productively infected with
HIV-2 produce less virus particles per replication cycle than
cells productively infected with HIV-1. This lower virus
production can be due to several viral genes that play a role at
post-entry and more downstream steps in the viral replication
cycle. Exact knowledge on which viral genes and steps in the
viral replication cycle involved in this phenotype is currently
under investigation.
Recently, Ariën et al. demonstrated that X4 HIV-2 isolates
are often out-competed by X4 HIV-1 isolates in in vitro
competition assays, indicating differences in replicative
capacity between late stage HIV-2 and HIV-1 as well
(Arien et al., 2005). Together these and our findings suggest
an intrinsic difference in the replicative capacity of HIV-1 and
HIV-2 in PBMC, a notion further supported by the apparently
similar replication rates of HIV-1 variants from AS/LTNP and
R5 HIV-2 variants from progressors. Marchant et al. recently
demonstrated that HIV-1 and HIV-2 variants have different
replication characteristics in macrophage cultures as well
(Marchant et al., 2006). The relatively impaired replication
capacity of HIV-2 in PBMC and macrophages may help
explain the relatively high level of virus control in HIV-2compared to HIV-1 infection, despite similar or even reduced
CD8+ T cell responses (Gillespie et al., 2005; Jaye et al.,
2004; Zheng et al., 2004).
Because long-term nonprogression (Marlink, 1996; Poulsen
et al., 1989, 2000; Larsen et al., 1998; Berry et al., 2002) and
efficient suppression of virus replication (Berry et al., 1998;
Gottlieb et al., 2002; Popper et al., 1999; Damond et al., 2002)
are frequently observed in HIV-2-infected individuals, our data
suggest that having a low replicative capacity is a common
phenotype for HIV-2 and that evolution to more rapid
replicating variants associated with disease progression occurs
less frequently than in HIV-1-infected individuals. Identifica-
tion of virus and/or host factors that determine the relatively low
replicative capacity of HIV-2 as well as those limiting evolution
will significantly contribute to our overall understanding of HIV
pathogenesis.
Patients and methods
Subjects and viruses
HIV-2 biological clones were obtained from 5 long-term
aviremic HIV-2-infected individuals and 6 individuals with
progressive disease, all participating in the Rotterdam cohort
(Table 1). With the exception of RH2-26 who is Caucasian, all
HIV-2-infected individuals are of West-African origin. HIV-1
biological clones were derived from 6 asymptomatically
infected individuals, four Caucasian and participants of the
Amsterdam Cohort studies on HIV-1 and AIDS (ACH), two of
West-African origin and participant of the Rotterdam cohort
(RH). One biological HIV-1 clone isolated from an individual
with AIDS was included as a reference virus. At the time of
virus isolation, none of the individuals received antiretroviral
therapy, with the exception of RH2-5 who was at the time
treated with, but not responding to, AZT/3TC.
Biological clones were isolated by co-cultivation of patient
PBMC with healthy donor PBMC in a limiting dilution fashion
as described elsewhere (Blaak et al., 1998, 2004). We favor to
perform virus isolation under limiting dilution conditions as this
allows one to obtain virus variants with varying biological
properties that co-exist within the viral quasispecies in vivo.
This in contrast to bulk virus isolations where only the fittest
variant(s) is (are) obtained. All virus stocks were grown
simultaneously in PBMC from one healthy donor. Infectious
virus titers of stocks were determined by analysis of concentra-
tions of functional RT enzyme (Marozsan et al., 2004) using an
ELISA-based RT activity detection kit (Lenti RT activity kit,
Caviditech, Uppsala, Sweden). All HIV-1 and HIV-2 variants
from asymptomatics were restricted to the use of CCR5
in PBMC as witnessed from their incapability to infect
CCR5Δ32/Δ32 PBMC (not shown), although in GHOST cells
the HIV-2 variants could use CXCR6 and GPR15 (Blaak et al.,
2005) and HIV-1 variants from RH1-2 could use CXCR6 (not
shown). The HIV-1 progressor variant was also restricted to the
use of CCR5, the HIV-2 progressor variants could either use
CCR5 or CXCR4 (Table 1).
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PBMC of healthy donors were isolated from buffy coats
using Ficoll-Paque PLUS (Amersham Biosciences Europe,
Freiburg Germany) and stored at −135 °C. All donors used in
experiments had the CCR5+/+ phenotype. Three days prior to
infection, PBMC were thawed and cultured in Iscoves modified
Dulbecco's medium (IMDM; Biowhittaker-Cambrex Bio Sci-
ence, Verviers, Belgium) supplemented with 10% Fetalclone II
(Hyclone, Perbio Science Nederland BV, Etten-Leur, The
Netherlands), 100 U/ml penicillin, 10 μg/ml streptomycin
(Biowhittaker), and 1 μg/ml phytohemagglutin (PHA; Murex,
Biotrading Benelux BV, Mijdrecht, The Netherlands). Upon
stimulation, PHA-blasts were either directly used or first
depleted of CD8+ T cells using anti-CD8 coated magnetic
beads (Dynal Biotech GmbH, Hamburg, Germany) according to
the instructions of the manufacturer. To increase depletion
efficiency, two consecutive rounds of depletion were performed.
After this treatment, the percentages of CD8+ T cells present in
the lymphocyte population were always less than 0.1% as
determined by flow cytometric analysis of cells stained with
Cy5-, FITC- and PE-conjugated monoclonal antibodies directed
against CD3, CD4 and CD8 respectively (DakoCytomation,
Glostrup, Danmark), using standard staining procedures.
Analysis of replication kinetics
PHA-stimulated cells (1.25 or 2.0 × 106) resuspended in
IMDM (Biowhittaker) supplemented with 10% Fetalclone II
(Biowhittaker), 20 U/ml recombinant interleukin-2 (rIL-2;
Proleukin, Chiron Benelux BV, Amsterdam The Netherlands)
and 4 μg/ml polybrene (Pb; Sigma-Aldrich Chemie, Schnell-
dorf, Germany) were exposed to inocula equalized for the
concentration of functional RT enzyme as a measure for
infectious virus (Marozsan et al., 2004) (250 or 500 pg RT per
infection, depending on the experiment). After 1 to 1.5 h of
incubation, cells were washed three times and resuspended in
rIL-2/Pb-containing medium to a final concentration of 1.106
per ml and transferred to 24-wells plates. In the case of 2-week
cultures, fresh PHA-blasts were added at day 7. Culture
supernatants were sampled every 2 days starting from day 1
and stored at −70 °C. As a measure for replication, concentra-
tions of functional RT in culture supernatants were measured
(Caviditech), representing newly produced virus particles.
Corrections were applied to correct for changes in culture
volumes as a result of sampling and the addition of fresh cells.
Replication rates
Replication rates were calculated based on the maximal
increase in RT concentration observed between the ‘lag-phase’
and the ‘plateau-phase’. Depending on virus and donor cell
combination, RT accumulation rates generally started declining
as of day 5 or 7, leaving only a short interval with optimal
growth (generally days 3 and 5 or days 5 and 7). To be able to
perform linear regression based on 2 data points, we included a
forced y-intercept value of 1 (i.e., increase was set relative to ‘1’for all variants), thereby assuming a constant replication rate as
of the moment of the first burst, which is probably around day 1
(Perelson et al., 1996). Thus, obtained regression curves
excellently fitted data observed during the interval of optimal
growth (see Fig. 3a).
Infectivity in CD8+ T cell-depleted PBMC
CD8+ T cell-depleted cells (2 × 106) were inoculated,
incubated for 1 h, washed and resuspended in 2 ml rIl-2/Pb-
containing medium of which 1.5 ml was transferred to 24-wells
plates and cultured to determine replication kinetics. Of the
remaining cells, 5 4-fold dilutions were made, starting with a
concentration of 4 × 105 cells/ml, and quadruplets of 100 μl
were transferred to 96-well plates and co-cultivated with
uninfected PHA-stimulated CD8+ T cell-depleted PBMC,
1.25.105 per well. Cultures were maintained for 21 days to
allow detection of virus production also in cultures where
initially one infected cell was seeded. At days 7 and 14, 1/3 of
the culture supernatants were removed, cultures resuspended
and 1/2 of the remaining volume transferred to fresh 96-wells
plates, containing freshly 3-day PHA-stimulated and CD8-
depleted PBMC. At day 21, culture supernatants were harvested
and analyzed for virus production. The frequency of infectious
units per million exposed cells (IUPM) was estimated from the
proportions of negative wells in the different cell dilutions using
a maximum likelihood method (Strijbosch et al., 1987).
Single cycle infectivity in GHOST-CCR5 cells
Single cycle infectivity was determined using GHOST-
CCR5 cells as described by others (Bleiber et al., 2001) with
slight modifications. GHOST cells cultured in RPMI (Biowhit-
taker) containing 10% Fetal Bovine Serum (FBS, Biowhit-
taker), hygromycin (100 μg/ml), geneticin (500 μg/ml) and
puromycin (1 μg/ml) were seeded in 24-well plates at 54,000
cells per well in selection medium 1 day prior to infection.
Each virus (400 pg RT in 500 μl RPMI + 10%FBS + 4 μg/ml
Pb) was added to 6 individual wells containing GHOST-CCR5
cells, and plates were centrifuged for 15 min at 2700 × g
(spinoculation) (Pietroboni et al., 1989). Plates were incubated
for another 2 h, after which inocula were removed and
selection medium was reapplied. For each virus variant one
well was harvested at 14, 17, 20, 23, 26 and 30 h after
infection. For this purpose, culture medium was removed and
cells incubated with 90 μl trypsin (GIBCO Invitrogen, Breda,
The Netherlands). Trypsin was inactivated by the addition of
300 μl PBS/20% FBS and cells were kept at 4 °C until they
were analyzed using a flow cytometer. Instrument settings
were adjusted so that the mean fluorescence in mock-infected
cells was approximately 101.
Statistical methods
Nonparametric tests were used for small groups (n < 9) and
when samples were not normally distributed. In cases where
log-transformation introduced normality, parametric tests were
153H. Blaak et al. / Virology 353 (2006) 144–154used on log-transformed values. Normality was determined
using Shapiro-Wilk. All analyses were performed using SPSS
11 for windows.
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